A Clinical Case of the Hereditary Transthyretin Amyloidosis

Author:

Reznik E. V.1ORCID,Nguyen T. L.2ORCID,Borisovskaya S. V.3,Brylev L. V.4ORCID,Zhelnin A. V.5ORCID,Seksyaev N. E.6ORCID

Affiliation:

1. Russian National Research Medical University (RNRMU) n.a. N.I. Pirogov; City Clinical Hospital n.a. V.M. Buyanov of Healthcare Department of Moscow; City Clinical Hospital n.a. V.P. Demikhov of Healthcare Department of Moscow; City Clinical Hospital № 31 of Healthcare Department of Moscow

2. Russian National Research Medical University (RNRMU) n.a. N.I. Pirogov

3. Russian National Research Medical University (RNRMU) n.a. N.I. Pirogov; City Clinical Hospital n.a. V.M. Buyanov of Healthcare Department of Moscow

4. City Clinical Hospital n.a. V.M. Buyanov of Healthcare Department of Moscow

5. Perm State Medical University named after Academician E.A. Wagner Ministry of Health of Russia

6. Perm Regional Clinical Hospital

Abstract

Introduction: Transthyretin (ATTR) amyloidosis is a severe rare disease with wide range of characters without specific symptoms including the damage to the peripheral nervous system and cardiac involvement. Case report: A 60-year-old female patient represented with weakness and paresthesia in the distal parts of the lower limbs, impeding walking for 2 years. Initially, symptoms were considered as a manifestation of degenerative stenosis of the lumbar spine, decompressive laminectomy was performed but the symptoms after surgical treatment persisted. Based on data from clinical and electroneuromyographic examinations, axonal sensorimotor polyneuropathy was diagnosed. Genetic testing of the patient, her elder sister, son and daughter using the Sanger sequencing method detected a variant of the nucleotide sequence in the fourth exon of the transthyretin gene (Chr18: 29178562, rs148538950, NM_000371.3: c.G368A: p. Arg123His) in the heterozygous state. A subcutaneous fatty tissue biopsy of abdominal wall with a Congo red stain and polarized light examination revealed amyloid microdeposits, grade CR 1+ (minimal deposits), confirmed the diagnosis of familial ATTR-amyloidosis. Echocardiography revealed concentric left ventricular wall thickening with normal end diastolic size and volume, preserved ejection fraction, left atrial enlargement, pulmonary hypertension and type 1 diastolic dysfunction. Specific anti-amyloid therapy — tafamidis was prescribed. Conclusion: In patients with peripheral polyneuropathy and left ventricular hypertrophy of unknown etiology, a complex examination is necessary for the timely detection and treatment of amyloid polyneuropathy and cardiomyopathy.

Publisher

Synapse, LLC

Subject

General Medicine

Reference69 articles.

1. Hassan W, Al-Sergani H, Mourad W, Tabbaa R. Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management. Texas Heart Institute journal. 2005; 32(2): 178-84. PubMed PMID: 16107109; PubMed Central PMCID: PMC1163465.

2. Reznik E.V., Nguen T.L., Stepanova E.A. i dr. Amiloidoz serdtsa: vzglyad terapevta i kardiologa. Arkhiv\" vnutrennei meditsiny. 2020; 10(6): 430-457. https://doi.org/10.20514/2226-6704-2020-10-6-430-457 Reznik E.V., Nguyen T.L., Stepanova E.A. et al. Cardiac Amyloidosis: Internist and Cardiologist Insight. The Russian Archives of Internal Medicine. 2020; 10(6): 430-457. https://doi.org/10.20514/2226-6704-2020-10-6-430-457 [in Russian].

3. Lysenko (Kozlovskaya) L.V., Rameev V.V., Moiseev S.V. i dr. Klinicheskie rekomendatsii po diagnostike i lecheniyu sistemnogo amiloidoza. Klin farmakol ter. 2020; 29(1): 13-24 Lysenko (Kozlovskaya) L.V., Rameev V.V., Moiseev S.V., et al. Clinical guidelines for diagnosis and treatment of systemic amyloidosis. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Therapy 2020; 29(1): 13-24. DOI 10.32756/0869-5490-2020-1-13-24 [in Russian]

4. Benson M.D., Buxbaum J.N., Eisenberg D.S. et al. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2020; 27(4): 217- 22. doi: 10.1080/13506129.2020.1835263. PubMed PMID: 33100054.

5. Yamamoto H., Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC heart failure. 2019; 6(6): 1128-39. doi: 10.1002/ehf2.12518. PubMed PMID: 31553132; PubMed Central PMCID: PMC6989279.

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Systemic amyloidosis in a patient with acute heart failure;The Clinician;2024-09-01

2. Transthyretin mutagenesis: impact on amyloidogenesis and disease;Critical Reviews in Clinical Laboratory Sciences;2024-06-07

3. Cardiac amyloidosis, features of diagnosis and treatment;Clinical Medicine (Russian Journal);2024-04-15

4. Differential Diagnosis of Cardiac Amyloidosis and Hypertrophic Cardiomyopathy;The Russian Archives of Internal Medicine;2023-10-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3